Inactive Instrument

Albireo Pharma, Inc.

Equities

ALBO

US01345P1066

Biotechnology & Medical Research

Peter A. Zorn, Esq. Steps Down from as Chief Corporate Officer, General Counsel and Secretary of Albireo Pharma, Inc., Effective April 1, 2018

March 07, 2018 at 03:00 am IST

On February 28, 2018, Peter A. Zorn, Esq. stepped down from his positions as Chief Corporate Officer, General Counsel and Secretary of Albireo Pharma, Inc., effective April 1, 2018, to pursue other career opportunities.

Latest news about Albireo Pharma, Inc.

CAC40: in green, gains over 2% on a weekly basis	03/23/03	CF
CAC40: PMI and ISM data point to 22nd week of gains	03/23/03	CF
CAC40: 7350 in sight if rates continue to ease	03/23/03	CF
CAC40: breaks through 7300 pts after Bostic's comments	03/23/03	CF
Ipsen: acquisition of Albireo Pharma finalized	03/23/03	CF
French Drugmaker Ipsen Concludes Albireo Pharma Takeover	03/23/03	MT
Albireo Pharma, Inc. Announces Board Changes	03/23/03	CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from NASDAQ Composite Index	02/23/02	CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P TMI Index	02/23/02	CI
Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from S&P Global BMI Index	02/23/02	CI
Ipsen Biopharmaceuticals, Inc. completed the acquisition of Albireo Pharma, Inc. from a group of shareholders.	01/23/01	CI
Ipsen Extends Tender Offer for Albireo Pharma as It Awaits US Antitrust Clearance	22/23/22	MT
Ipsen: extension of the deadline for its tender offer for Albireo Pharma	22/23/22	CF
Albireo Pharma's Bylvay Granted Priority Review for Rare Genetic Disorder Alagille Syndrome Treatment	14/23/14	MT
Albireo Gets FDA Priority Review of Bylvay in Alagille Syndrome	14/23/14	DJ
Albireo Pharma, Inc. Announces U.S. Food and Drug Administration Accept Its Supplemental New Drug Application	14/23/14	CI
Insider Sell: Albireo Pharma	21/23/21	MT
Guggenheim Downgrades Albireo Pharma to Neutral From Buy	11/23/11	MT
Cowen Downgrades Albireo Pharma to Market Perform From Outperform, Adjusts Price Target to $48 From $68	11/23/11	MT
Jefferies Downgrades Albireo Pharma to Hold From Buy, Adjusts Price Target to $42 From $49	11/23/11	MT
North American Morning Briefing : Stock Futures -2-	11/23/11	DJ
Baird Adjusts Price Target on Albireo Pharma to $45 From $55, Maintains Outperform Rating	10/23/10	MT
HC Wainwright Downgrades Albireo Pharma to Neutral From Buy, Price Target is $42	10/23/10	MT
North American Morning Briefing : More Hawkish Fed -2-	10/23/10	DJ
Top Midday Gainers	10/23/10	MT

Chart Albireo Pharma, Inc.

Duration

Period

More charts

Company Profile

Albireo Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its product, Bylvay, is for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) ages three months or older and is authorized in Europe for the treatment of PFIC in patients ages six months or older. Its product candidate elobixibat is licensed for the treatment of chronic constipation and other functional diseases in Japan and other select markets in Asia. Its lead candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) where systemic bioavailability has been demonstrated in preclinical and clinical studies. Its preclinical candidate for adult viral and liver diseases includes A2342.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs